Here, we identify targetable signaling pathways in T-ALL, and demonstrate the in vitro cytotoxicity of novel agents, including mTOR/PI3K inhibitors (gedatolisib, AZD2014, and LY3023414), G2M checkpoint inhibitors (AZD7762, PHA-793887, and AT7519) and NAMPT inhibitors (FK866 and STF-118804). This evidence concerns the gene MTOR and acute lymphoblastic leukemia.